Merrimack Pharmaceuticals (NASDAQ: MACK) is one of 190 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Merrimack Pharmaceuticals to similar companies based on the strength of its dividends, profitability, earnings, institutional ownership, risk, valuation and analyst recommendations.
This table compares Merrimack Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Merrimack Pharmaceuticals Competitors||-4,492.13%||-554.59%||-43.16%|
52.6% of Merrimack Pharmaceuticals shares are held by institutional investors. Comparatively, 47.5% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 8.5% of Merrimack Pharmaceuticals shares are held by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a breakdown of current ratings for Merrimack Pharmaceuticals and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Merrimack Pharmaceuticals Competitors||543||2475||6712||128||2.65|
Merrimack Pharmaceuticals presently has a consensus price target of $15.00, suggesting a potential upside of 44.93%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.82%. Given Merrimack Pharmaceuticals’ higher probable upside, equities analysts plainly believe Merrimack Pharmaceuticals is more favorable than its peers.
Risk & Volatility
Merrimack Pharmaceuticals has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Comparatively, Merrimack Pharmaceuticals’ peers have a beta of 1.57, indicating that their average stock price is 57% more volatile than the S&P 500.
Earnings & Valuation
This table compares Merrimack Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Merrimack Pharmaceuticals||$144.27 million||-$151.74 million||0.30|
|Merrimack Pharmaceuticals Competitors||$217.29 million||-$39.39 million||-65.42|
Merrimack Pharmaceuticals’ peers have higher revenue and earnings than Merrimack Pharmaceuticals. Merrimack Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Merrimack Pharmaceuticals peers beat Merrimack Pharmaceuticals on 7 of the 12 factors compared.
About Merrimack Pharmaceuticals
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development. Its advanced program is its therapeutic MM-398, which it markets in the United States under the brand name ONIVYDE. Its other clinical stage product candidates include MM-121, MM-141, MM-310, MM-302 and MM-151. The Company is developing in vitro and in vivo diagnostics for use with each of its oncology therapeutic product candidates. Its in vitro diagnostic agents employ biophysical or biochemical markers of cancer, or biomarkers. Its in vivo diagnostics take the form of imaging agents that may help identify patients likely to benefit from its therapeutic products by measuring deposition of its products in the tumor.
What are top analysts saying about Merrimack Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merrimack Pharmaceuticals and related companies.